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SCREENING AND MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES
Abstract
Purpose: This purpose of this project was to evaluate preventive screening practices and
adherence to guidelines for patients with type 2 diabetes (T2DM) as recommended by the
American Diabetes Association (ADA) and United States Preventive Services Task Force
(USPSTF) in the primary care setting. The specific aims were to: 1) determine the percentage of
patients who received recommended screenings from the ADA, 2) determine the percentage of
patients who received recommended screenings from the USPSTF, and 3) determine if the
proportion of patients to receive the recommended screenings met established benchmarks set by
Healthy People 2020 (HP2020).
Methods: A retrospective medical record review to assess the screening and management of
patients with T2DM was performed. The medical records were reviewed for screening of ADA
and USPSTF recommendations during routine office visits. A random sample of 100 patient
medical records meeting inclusion criteria were chosen for review. Patient demographics and
screenings were recorded in a spreadsheet and exported to SPSS to analyze the data.
Results: The results demonstrated that screening rates for hemoglobin A1C, cholesterol, obesity,
blood pressure, tobacco use, and kidney function met or exceeded HP2020 goals. Preventive
services that did not meet HP2020 goals included screening for cancers, osteoporosis,
vaccinations, foot exams, and eye exams.
Conclusion: This study offers insight into possible gaps in managing T2DM in primary care, as
well as areas that need further research. Providers should screen patients based on clinical
practice guidelines to reduce the risk of developing complications associated with T2DM and
prevention of other comorbidities. Additional research with larger, more diverse samples should
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be performed, as well as provider and patient focus groups to examine barriers in screening
patients with T2DM in primary care.
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An Evaluation of the Screening and Management of Patients with Type 2 Diabetes
Introduction
Type 2 diabetes mellitus (T2DM) is a serious health concern and economic burden that
affects more than 29 million Americans (American Diabetes Association [ADA], 2014). Patients
with T2DM are at increased risk of having complications and comorbidities that affect morbidity
and mortality. With preventive screenings according to guideline recommendations, many of
these complications or comorbidities could be prevented, or detected early, when treatment
works best. Primary care providers are in a key position to provide appropriate screenings to
improve outcomes and decrease costs for patients with T2DM. Nationally, Americans receive
preventive services at about half the recommended rate (CDC, 2015). This gap analysis was
conducted to gain a better understanding of the screening practices and management of patients
with T2DM in the primary care setting.
Background
In 2013, T2DM affects approximately 29 million people or 9.3% of the population in the
United States (U.S.) and was the seventh leading cause of death (ADA, 2014). Based on reports
from the CDC, the projected prevalence of T2DM is estimated to increase to 33% in 2050 in the
U.S. (Boyle et al., 2010). In Kentucky, the incidence of adult T2DM increased from 3.5% of all
adults in 1995 to 10.6% of adults in 2013 (KDR, 2015). The Louisville Metropolitan area is also
above the national average with approximately 13.2% of adults diagnosed with T2DM in 2015
(KDR, 2009). In 2012, T2DM resulted in approximately $245 billion in healthcare costs (ADA,
2014). Average medical costs for patients with T2DM are 2.3 times higher than patients without
a diagnosis of T2DM (ADA, 2014).
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T2DM can lead to complications of retinopathy, nephropathy, neuropathy, limb
amputations, and cardiovascular disease (ADA, 2015). These complications are primarily
related to vascular changes caused by poor blood pressure, lipid, and glycemic control. Early
detection and treatment of these modifiable risk factors can reduce the risk of developing
complications (ADA, 2015). Screening and management according to national guidelines can
significantly reduce cardiovascular risk factors and progression to end-stage T2DM.
Patients with T2DM are not only at increased risk of developing complications related to
poor glycemic control, but they often have other chronic diseases or conditions as well. Most
patients with T2DM have at least one chronic comorbidity and as many as 40% have three or
more chronic health conditions (Piette & Kerr, 2006). The major comorbidities of T2DM are
obesity, dyslipidemia, hypertension, chronic kidney disease, and cancers (AACE, 2016).
Screening for comorbidities can help to detect conditions early when treatment is most effective
(CDC, 2013).
ADA Screening Recommendations
The ADA Standards of Medical Care (2015) identified key components of quality care
that have been shown to improve outcomes for patients with T2DM. The components identified
include: monitoring the hemoglobin A1C at least twice yearly, cholesterol screening, yearly
urinary microalbumin excretion, annual dilated eye exam, routine foot exams, yearly influenza
vaccination, and pneumococcal vaccinations. Other recommendations to decrease
cardiovascular risks include statin therapy and aspirin therapy, as well as the treatment of
hypertension with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor
blocker (ARB).
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Glycemic Control. A1C has a strong predictive value for diabetes complications and it
is recommended for patients to be tested at least twice yearly. Monitoring A1C is an indicator of
glycemic control and a percentage point drop in A1C from 8% to 7% can reduce cardiovascular
death by 45% (Eeg-Olofsson, 2012). This drop can lead to $564 in cost savings per patient per
year (Rui et al., 2010).
Cardiovascular Disease. Patients with T2DM are more likely to have hypertension and
dyslipidemia leading to increased risk of cardiovascular disease. Blood pressure control reduces
the risk of cardiovascular events by as much as 41% (Law, Morris, & Wald, 2009). Blood
pressure should be measured at every visit and patients with blood pressure over 140/90 should
be treated with an ACE or ARB as first line therapy. ACE and ARB medications have been
found to prevent or delay diabetic kidney disease. Aspirin therapy is recommended for patients
50 years and older who are at increased cardiovascular risk to reduce the risk of a vascular event
(i.e. myocardial infarction or stroke). Further, patients should have lipid levels measured at least
yearly or more often as needed. All patients aged 40 and over and patients less than 40 with
cardiovascular risk factors should be on at least moderate to high intensity statin therapy (ADA,
2015).
Nephropathy. Approximately 20-40% of patients with diabetes develop nephropathy
compared to 3.3% of the general population (Chen, 2014). Abnormal levels of albuminuria are
the earliest clinical evidence of nephropathy. Albuminuria and glomerular filtration rate should
be screened yearly to assess for nephropathy. Treatment with an ACE or ARB should be initiated
with elevated levels (ADA, 2015).
Neuropathy. The incidence of peripheral neuropathy in patients with T2DM is 59%
compared to 2.4% of the general population (Hughes, 2002). Patients with diabetes are at an
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increased risk of foot ulcerations related to peripheral neuropathy and should be screened at least
annually. The foot exam should include assessment of pedal pulses and monofilament testing
(ADA, 2015).
Diabetic Retinopathy. Diabetic retinopathy is the leading cause of blindness in patients
aged 20-74 (ADA, 2015). Screening for retinopathy can identify the condition early when
treatment is more likely to prevent loss of vision. Patients should have initial dilated eye exam
upon diagnosis and annual dilated eye exams to screen for retinopathy. After two years of
normal exams, patients may consider lengthening that interval to once every two years (ADA,
2015).
Vaccinations. Patients with T2DM are at increased risk of preventable infectious
diseases. Death related to influenza and pneumonia is four times more likely for patients who
have diabetes than for those who do not (ADA, 2015). These patients should receive annual
influenza vaccinations. In addition, they should receive pneumococcal vaccinations (i.e.
pneumococcal conjugate vaccine 13 followed by pneumococcal polysaccharide 23).
USPSTF Screening Recommendations
Under the Affordable Care Act, insurance companies, including Medicare, provide yearly
wellness exams at no cost to the patient. The purpose of the yearly exam is to identify an
individualized preventive care plan for each patient. The preventive care plan is based on United
States Preventive Services Task Force (USPSTF) recommendations. The USPSTF is a panel of
experts that make recommendations for preventive screening based on evidence-based medicine
(USPSTF, 2015).
USPSTF A or B grade recommendations were used to identify patients appropriate for
screening in this study. A and B grade recommendations are given to services that provide a
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substantial to moderate benefit. Grade C recommendations are given to services that offer small
net benefits and should only be offered to patients depending on individual circumstances.
Grade D recommendations are given to services that should be discouraged where the harm of
the service outweighs the benefits. Grade I recommendations are given to services when there is
insufficient evidence to conclude the benefits outweigh harms, and if the service is offered the
patient should understand the uncertainty of the benefits (USPSTF, 2015).
The goal of the recommendations is to offer providers and patients strategies to prevent
illness and improve health. Current recommendations for screening in all adults include: blood
pressure, osteoporosis, obesity, tobacco use, and breast, colorectal, cervical, and lung cancer.
These recommendations vary with age and gender (see Appendix A for information on USPSTF
recommended screenings). Screening patients with T2DM according to current USPSTF
recommendations is particularly important because these patients are at increased risk for
developing comorbidities.
Blood Pressure. All adults should be screened for hypertension and measurements
should be obtained from outside of the clinical setting before diagnosis and treatment. The goal
for patients under the age of 60 is to maintain blood pressure under 140/90, and for patients over
the age of 60 the goal is under 150/90 (USPSTF, 2015).
Cancer. While the exact mechanism is unclear, patients with T2DM have been shown to
be at an increased risk of developing breast, colorectal, cervical, lung, and other cancers (Vigneri
et al., 2009). Breast cancer is the second leading cause of cancer death and the most commonly
diagnosed cancer for women after skin cancer (American Cancer Society [ACS], 2016). Patients
with T2DM have a 20-27% increased risk for developing breast cancer (Boyle et al., 2012).
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Breast cancer screening is recommended every 1-2 years for all women age 50-74 (USPSTF,
2016).
Cervical cancer was once a leading cause of cancer death for women; however, with the
increase in screening, the death rate has decreased by more than 50% (ACS, 2016). Cervical
cancer screening is recommended every three years for women ages 21-65 with cytology or for
women ages 30-65 every five years with combination cytology and human papillomavirus
testing (USPSTF, 2012).
Colorectal cancer is the third leading cause of cancer deaths (ACS, 2016). Patients with
T2DM have a 1.3-fold increased risk for colorectal cancer compared to the general population
(Paul et al., 2015). Colorectal cancer screening is recommended starting at age 50 and
continuing until age 75, or sooner for those with other risk factors such as family history
(USPSTF, 2016).
Lung cancer is the leading cause of cancer death for men and women (ACS, 2016). The
detection and treatment of early stage lung cancer can decrease morbidity and mortality.
Screening is recommended for adults age 55-80 with a 30 pack-year smoking history.
Counseling for tobacco cessation is the most important intervention for prevention of lung cancer
(USPSTF, 2013).
Osteoporosis. Patients with T2DM are at increased risk of an osteoporosis-related
fracture and should be screened and offered treatment to reduce this risk (Hamann et al., 2012).
Women age 65 and older and younger women with increased risk factors should be screened for
osteoporosis using dual-energy x-ray absorptiometry of the hip and lumbar spine. Other factors
associated with increased risk for osteoporosis include smoking, alcohol use, and personal and
parental history of fracture (USPSTF, 2011).
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Obesity. Obesity management can delay progression of T2DM and improve glycemic
control (ADA, 2015). Obesity screening using body mass index (BMI) should be calculated
regularly. Patients with a BMI >30 should be counseled by their primary care provider to
include comprehensive weight management strategies. Also, referral to a nutritionist, an
exercise therapist, a behavioral therapist or weight management programs have been found to be
effective strategies (USPSTF, 2012).
Tobacco Use. Patients with T2DM who smoke are at higher risk for kidney disease,
blindness, and circulatory complications leading to amputations (U.S. Department of Health and
Human Services, 2014). All adults should be screened for tobacco use. Patients who do use
tobacco should be advised to stop and provided behavioral interventions and pharmacotherapy
for cessation (USPSTF, 2015).
Healthy People 2020
Many of the ADA and USPSTF recommendations have Healthy People 2020 (HP2020)
goals set to increase the proportion of patients that are screened (see Appendix B for information
on the national screening goals). HP2020 sets 10-year national objectives for improving the
health of all Americans. It has established benchmarks and monitors progress of these
objectives. The objectives are made in an effort to increase collaboration among healthcare
providers, empower individuals to make informed health decisions, and measure the impact of
prevention activities. The national rates for screening of preventive services fall below the target
rate for all of the ADA and USPSTF recommended preventive screenings (HP2020, 2016).
Center for Medicare and Medicaid Services
In 2017, the Center for Medicare and Medicaid Services (CMS) will implement the
Quality Payment Program that is part of the Medicare Access and CHIP Reauthorization Act of
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2015 (MACRA). This payment program will affect how providers will be reimbursed for the
quality of services provided. The new payment model will replace previous reporting programs
(i.e. Meaningful Use, Physician Quality Reporting System, and Value-Based Payment Modifier)
but will continue to use similar measures of performance as used in the previous programs.
Based on the quality of care provided in 2017, the program will use positive, neutral, or negative
payment adjustments from 4% in 2019 up to 9% in 2022. Providing preventive services and
evidence-based management of chronic conditions is key to this payment model, in an effort to
improve the care and outcomes for patients (CMS, 2016).
Study Purpose
The incidence of T2DM continues to increase every year, and it is of the utmost
importance to improve outcomes for patients and decrease costs associated with complications
and comorbidities. The purpose of this study was to evaluate preventive screening practices and
adherence to guidelines for patients with T2DM as recommended by the ADA and USPSTF in
the primary care setting. The HP2020 rates were used as a benchmark for data comparison.
The specific objectives were to:
1. Determine the percentage of patients who received ADA recommended screenings
and preventive services, including: hemoglobin A1C, cholesterol, kidney function, foot
exams, eye exams, influenza and pneumococcal vaccinations, and medications to
decrease cardiovascular risk (i.e. statin, aspirin, ACE, or ARB).
2. Determine the percentage of patients who have received USPSTF recommended
screenings, including: blood pressure, cholesterol, osteoporosis, obesity, tobacco use, and
cancer screenings as appropriate for age and gender.
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3. Determine if the proportion of patients to receive the recommended screenings met the
HP2020 established benchmarks.
Methods
Study Design and Setting
A retrospective electronic medical record (EMR) review of 100 medical records was
conducted to assess the percentage of patients with T2DM who received preventive screening
measures according to national guidelines. The setting of the study was a rural primary care
practice affiliated with a large healthcare system in a Midwestern city. This healthcare system
includes five hospitals, 27 primary care practices, 13 urgent care centers, and many specialty
offices. The screening rates at the practice site were compared to national benchmarks set by
HP2020.
Study Population
The inclusion criteria consisted of patients from the ages of 18 to 89. All patients had a
diagnosis of T2DM using International Classification of Diseases (ICD) codes (see Table 1 for
list of ICD codes used for inclusion). All office visits were for routine follow-up care for
diabetes from January 1, 2015 to December 31, 2015. There were no exclusion criteria.
Study Procedures
Permission for this study was obtained from the University of Kentucky’s Institutional
Review Board (IRB) and the Norton Healthcare Office of Research Administration (NHORA).
Data collection began following IRB approval and included a retrospective electronic medical
record review. No identifying information was obtained from patient records or reported in the
record review. Only the Principal Investigator (PI) of the project had access to the data collected
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from the EMR review. A request for waiver of informed consent was requested because this
study used existing patient medical records.
Medical records meeting inclusion criteria were identified by generating an electronic
report. Systematic sampling started with the third medical record and included every third
medical record until 100 medical records were selected. Each medical record was assigned a
study number. A cross-walk table of the study numbers and their correlated medical record
numbers was kept in a separate spreadsheet not available to anyone other than the PI. The
records were kept in a personal password protected computer.
The record review and data collection were completed during August 2016. To evaluate
screening recommendations and services provided, data collected included documentation of
A1C, cholesterol, kidney function, foot exams, eye exams, vaccinations, medications to decrease
cardiovascular risk, cancer screenings, blood pressure, obesity, tobacco use, and osteoporosis
screening. Patient demographic data collected included age, insurance coverage, gender, and
ethnicity.
Data Analysis
The de-identified data collected by the PI was entered into an Excel spreadsheet and
exported to Statistical Package for the Social Sciences (SPSS) software for statistical analysis.
Descriptive statistics including frequencies and means were used to assess demographics and
screening recommendations. Screening rates for this practice were compared to national rates
and target goals set by HP2020.

12

SCREENING AND MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES
Results
Sample Characteristics
Demographics were analyzed to understand the characteristics of the randomly selected
medical records (see Table 2). Of the 100 records selected for review, 51 (51%) were female
patients and 49 (49%) were male patients. Age ranged from 29 to 88 with a mean age of 60 (SD
11.21). Seventy-nine percent were Caucasian, 15% were African American, and 6% were of
other ethnicities. The majority of patients (56%) had Medicare or Medicaid insurance, 40% had
private insurance, and 4% had other insurance plans.
ADA and USPSTF Recommended Screenings
The ADA and USPSTF screenings were evaluated to determine the percentage of patients
meeting the national guidelines (see Table 3).
Obesity. Body mass index (BMI) was calculated on all patients at each visit in the
medical record. BMI ranged from 18.7 to 59.5 with a mean BMI of 34.3 (SD 7.38). According
to BMI results, 76% were obese with a BMI greater than 30 and 19% were extremely obese with
a BMI over 40. Of those with obesity, only 16 patients (21%) had a diagnosis of obesity in their
medical record.
Smoking status. All patients had documentation of screening for smoking status and
19% of patients were current tobacco users.
A1C. A1C levels were drawn on all patients at least once during 2015 and 77% of
patients had A1C levels drawn two or more times during the year. The A1C levels ranged from
4.9 to 14.2 with an average of 7.7 (SD 2.0).
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Kidney Function. Ninety-five percent of patients received screening of glomerular
filtration rate and urinalysis to evaluate microalbuminuria. This study did not evaluate abnormal
results for kidney function.
Cholesterol. Cholesterol levels were obtained taken on all patients except one (99%).
Seventy-six percent of patients had a diagnosis of hyperlipidemia. Eighty-one percent of patients
were prescribed medications for hyperlipidemia. Seventy-five percent of patients were
specifically treated with a statin medication as recommended by the ADA.
Blood Pressure. Blood pressure was measured on all patients. Eighty-four percent of
patients had a diagnosis of hypertension and 90% of patients were prescribed medications for
hypertension. Seventy-six percent of patients were prescribed an ACE or ARB as recommended
by the ADA. Twenty-four percent of patients had an elevated blood pressure reading recorded in
their record.
Foot and Eye Exams. Only 53% of patients had documentation of having a foot exam
and 54% had documentation of an eye exam.
Vaccinations. Forty-three percent of patients received the flu vaccination. Of the 64
patients between the age of 18 to 64, nineteen patients (29.7%) received the pneumococcal
vaccination. Of the 36 patients age 65 and older, twenty-six patients (72.2%) received the
pneumococcal vaccine.
Cancer and Osteoporosis Screening. Thirty-nine women met the criteria for breast
cancer screening and 29 women (74%) received appropriate exams. Eighty-one patients met the
criteria for colorectal cancer screening and 51 patients (63%) received appropriate screening.
Thirteen patients met criteria for lung cancer screening and four patients (30.8%) received
appropriate screening. Twenty-eight women met the criteria for cervical cancer screening and 13
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patients (46.4%) received appropriate screenings. Twenty-five patients met the criteria for
osteoporosis screening and 20 women (80%) received appropriate screening.
Discussion
The purpose of this study was to determine if specific preventive screening practices
were documented for patients with T2DM and if ADA and USPSTF guideline recommendations
were implemented. This study provided insight into the preventive screening practices and
implementation of ADA and USPSTF recommendations for patients with T2DM. This study did
not address lack of provider recommendation, patient nonadherence, or changes in treatment
related to abnormal screening findings.
At this practice site, the results demonstrated that some of the ADA and USPSTF
recommendations exceeded national and HP2020 goals while other goals fell short (see
Appendix B). ADA screening recommendations that met or exceeded HP 2020 goals included
A1C measurements twice per year, cholesterol, and kidney function. USPSTF screening
recommendations that met or exceeded HP2020 goals included obesity, blood pressure, and
tobacco use. ADA and USPSTF screening rates that did not meet HP2020 goals included all
cancer screenings, osteoporosis, vaccinations, and foot and eye exams.
Screening rates that exceeded HP2020 goal rates could be in part related to the use of an
EMR that utilizes clinical decision support tools (CDST). The use of EMRs with CDSTs has
been shown to increase preventive services in the primary care setting (Friedman et al., 2016).
This healthcare system implemented the EMR system, EPIC, in 2012 in their primary care
practices. EPIC uses CDSTs that use best practice advisories for providers that auto-populate
screening recommendations. The CDSTs are integrated into EPIC to identify patients due for
preventive screenings. The CDSTs also have flowsheets for chronic diseases such as T2DM
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with checklists of condition-specific recommendations. However, providers must use the
CDSTs and patients must adhere to the recommendations for screening rates to improve.
Of the screenings that exceeded HP2020 goals, this healthcare system currently has
practices in place to implement some of these measures on a routine basis. Tobacco, obesity,
and blood pressure screenings are obtained at each visit. It was noted that more patients were
taking antihypertensive medications than had an ICD-9 diagnosis of hypertension. This could be
related to patients taking ACE or ARB for kidney protection, or lack of documentation of the
diagnosis code. Other measures that exceeded HP2020 goals included A1C, cholesterol, and
kidney function. These rates could be higher related to the use of the CDST for chronic diseases.
Screening rates that did not meet the HP2020 goals could be related to documentation
practices. Screenings were documented in various locations of the medical record to include the
health maintenance section, visit encounter note, or other areas. For instance, colon cancer
screenings were listed in the health maintenance section of some records and in some cases they
were not documented at all, only scanned into a media tab; this could lead to falsely lower rates
of screening.
Cervical cancer screening fell below the target and national average in this study. The
low cervical cancer screening rates could be related to patients having the exam done at a
specialist office or not meeting requirements (e.g. having had a hysterectomy), and providers not
documenting this appropriately in the record. Foot exams also fell below the target and national
averages. Low rates for foot exams could be related to documentation practices, as some
providers documented this exam in the health maintenance section, while other providers
included this exam in their visit encounter note.
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Additionally, this study did not assess patient factors associated with low screening rates.
Research indicates that patient non-adherence to provider recommendations accounts for 40% to
70% of missed preventive services (Martin et al., 2005). Factors that affect patient adherence to
provider recommendations include health beliefs, literacy, costs, and patient-provider
relationship (Martin et al., 2005).
Limitations
The study was a retrospective medical record review and can only be used to identify
gaps in the preventive screening rates of patients with T2DM. Study limitations include small
sample size (N=100) from one primary care office, lack of diversity of patients, and the location
of the practice. These limitations limit the study results from being generalizable to other
primary care offices.
The current EMR was implemented shortly before this study was conducted. The
providers had previously used paper medical records and might not have been as familiar with
documenting in the EMR or using the CDST available. In addition, this study only considered
documented screenings and did not assess for lack of provider recommendation or patients that
did not adhere to recommendations.
Recommendations
Recommendations for future studies include further investigation of preventive screening
practices of patients with T2DM in the primary care setting. For study results to be more
generalizable to other practices in this healthcare system, studies should include offices
throughout the region and include a larger, more diverse sample. To improve screening rates at
this practice site, future studies should incorporate provider and patient surveys or focus groups
to determine other barriers to preventive screenings.
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Interventions to improve screening rates should focus on increasing provider
recommendations and improving patient adherence. Interventions to improve provider
recommendations should include education of the guideline recommendations and CDST
available on the EMR. Provider education may lead to a more uniform patient record amongst
providers improving documentation and screening rates. Interventions to improve patient
adherence should include patient reminders such as letters, postcards, or telephone calls. Letters
sent as reminders to patients have been shown to be an effective method for increasing cervical
cancer screening (Hitzeman & Xavier, 2012).
Patient education on the importance of preventive screenings is another key intervention
that could lead to improved screening rates. Printed education is currently provided to patients at
the end of each visit on an after-visit summary (AVS). The AVS includes educational material
related to the visit diagnosis and can be individualized by providers. Preventive screening
reminders and related information could be added to the AVS.
Patient education can also be done one-on-one with the provider or other office staff such
as nurse navigators. Nurse navigators are being integrated into many of the primary care
practices in this particular healthcare system, including the study practice site. The nurse
navigators collaborate with the patient’s care team to provide education and support services as
needed.
Additionally, the majority of appointments in this study were scheduled as a chronic visit
follow-up appointment. Providers have limited time to see each patient and can be overwhelmed
by the chronic condition, comorbidities, screening and treatment needs of the patient with T2DM
(Piette & Kerr, 2006). This leaves providers to prioritize services and defer some services to
future visits (Yarnell et al., 2003). Scheduling appointments specifically for annual wellness
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visits could provide time to address preventive screenings. Future research is recommended to
determine if adding these interventions would lead to improved screening rates.
Conclusion
T2DM is one of the leading health concerns for this nation. This serious health concern
can lead to costly complications and comorbidities. Primary care providers are in a key position
to help patients make informed decisions with regard to recommended screenings. Current
guidelines recommend screening to prevent illness and improve health for patients with T2DM.
The new CMS payment models will require preventive services as part of reimbursement.
The purpose of this study was to gain a better understanding of the current practices
associated with screening recommendations for patients with T2DM in a primary care setting.
While some areas of screening were above national goals, there were many areas where the goals
were not being met. Further research is needed to identify gaps in preventive screening
recommendations in the primary care setting. Identifying gaps and implementing interventions
to improve screening of patients with T2DM will lead to improved outcomes and decreased
costs.
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Table 1
ICD-9 Codes used for Inclusion Criteria
250.0 Diabetes mellitus without mention of complication
250.00 Diabetes mellitus without complication type 2 or unspecified type not stated
as uncontrolled
250.02 Diabetes mellitus without complication type 2 or unspecified type
uncontrolled
250.1 Diabetes with ketoacidosis
250.10 Diabetes mellitus with ketoacidosis type 2 or unspecified type not stated as
uncontrolled
250.12 Diabetes mellitus with ketoacidosis type 2 or unspecified type uncontrolled
250. 4 Diabetes with renal manifestations
250.40 Diabetes mellitus with renal manifestations type 2 or unspecified type not
stated as uncontrolled
250.42 Diabetes mellitus with renal manifestations type 2 or unspecified type
uncontrolled
250.5 Diabetes with ophthalmic manifestations
250.50 Diabetes mellitus with ophthalmic manifestations type 2 or unspecified type
not stated as uncontrolled
250.52 Diabetes mellitus with ophthalmic manifestations type 2 or unspecified type
uncontrolled
250.6 Diabetes with neurological manifestations
250.60 Diabetes mellitus with neurological manifestations type 2 or unspecified type
not stated as uncontrolled
250.62 Diabetes mellitus with neurological manifestations type 2 or unspecified type
uncontrolled
250.7 Diabetes with peripheral circulatory disorders
250.70 Diabetes mellitus with peripheral circulatory disorders type 2 or unspecified
type not stated as uncontrolled
250.72 Diabetes mellitus with peripheral circulatory disorders type 2 or unspecified
type uncontrolled
250.9 Diabetes with unspecified complication
250.90 Diabetes mellitus with unspecified complication type 2 or unspecified type
not stated as uncontrolled
250.92 Diabetes mellitus with unspecified complication type 2 or unspecified type
uncontrolled
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Table 2
Sample Characteristics (N=100)
Variable
Age
Gender
Male
Female
Ethnicity
Caucasian
African American
Other
Insurance
Medicare/Medicaid
Private
Other

n (%)

Mean (SD)
60 (11.21)

49 (49)
51 (51)
79 (79)
15 (15)
6 (6)
56 (56)
40 (40)
4 (4)
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Table 3
Evaluation of ADA and USPSTF Recommended Screenings (N=100)
n (%)
Mean (SD)
Variable
34.3 (7.4)
BMI
Obese BMI ≥30
76 (76)
Extremely obese BMI ≥40
19 (19)
BMI diagnosis
16 (21)
7.7 (2.0)
Hemoglobin A1C
A1C levels drawn once
100 (100)
A1C levels drawn ≥ twice
77 (77)
ADA Specific Recommendations
Kidney function
95 (95)
Eye exam
54 (54)
Foot exam
53 (53)
Aspirin
43 (43)
Blood pressure
Screened
100 (100)
Hypertension diagnosis
84 (84)
Hypertension medication
90 (90)
ACE or ARB
76 (76)
Elevated blood pressure reading
24 (24)
Cholesterol
Screened
99 (99)
Hyperlipidemia diagnosis
76 (76)
Hyperlipidemia medication
81 (81)
Statin
75 (75)
Smoking
Screened
100 (100)
Smoker
19 (19)
Non-smoker
81 (81)
Vaccinations received
Influenza
43 (43)
Pneumococcal 18-64 (n=84)
19 (29.7)
Pneumococcal 65 and older (n=38)
26 (72.2)
Cancer Screenings
Breast (n=39)
29 (74.4)
Cervical (n=28)
13 (46.4)
Colorectal (n=81)
51 (63.0)
Lung (n=13)
4 (30.8)
Osteoporosis Screening (n=25)
20 (80)
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Appendix A
USPSTF Recommendations for Screening
Topic
Blood Pressure
screening
Cholesterol

Gender
Male and
Female
Men

Age
18 and older

Female

20 to 45

Male
Female

20 to 35
45 and older

Osteoporosis

Female

65 and older

Obesity

Male and
Female

18 and older

Tobacco

Male and
Female

18 and older

Breast Cancer

Female

50 to 74

Colorectal Cancer

Male and
Female
Male and
Female

50 to 75

Female

21 to 65

Lung Cancer

Cervical Cancer

35 and older

55 to 80

Recommendation
Obtain measurements outside of the clinical setting for
diagnostic confirmation before starting treatment.
Screen for lipid disorders (total cholesterol and HDL-C) to
identify asymptomatic men and women who are eligible for
preventive therapy.
Screen for lipid disorders (total cholesterol and HDL-C) if
they are at increased risk for coronary heart disease to
identify asymptomatic men and women who are eligible for
preventive therapy.
Screen for osteoporosis using a dual-energy x-ray
absorptiometry of the hip and lumbar spine and quantitative
ultrasonography of the calcaneus.
Screen using BMI and offer obese adults referral to
intensive behavioral interventions to improve weight status
and other risk factors for important health outcomes.
Ask all adults about tobacco use, advise them to stop using
tobacco, and provide behavioral interventions and
pharmacotherapy for cessation.
Biennial screening mammography for women aged 50 to
74.
Screen using fecal occult blood testing, sigmoidoscopy, or
colonoscopy.
Screen patients using a low-dose CT who have a 30 packyear smoking history and currently smoke or who have quit
within the past 15 years.
Screening with cytology every 3 years. (For women ages
30 to 65, may lengthen interval to 5 years with combination
of cytology and HPV testing).
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Appendix B
Healthy People 2020 Current Screening Rate, Goal Screening Rate, and Study Practice Site
Screening Rate
National
Rate

Target
Rate

Study
Rate

Proportion of adults with diabetes who have an A1C
twice a year

64.6

71.1

77

Proportion of adults who have had their blood
cholesterol levels checked within the preceding five
years

74.6

82.1

99

Proportion of adults with diabetes who have a yearly
eye exam

53.4

58.7

54

Proportion of adults with diabetes who have a yearly
foot exam

68.0

74.8

53

Proportion of adults with diabetes who have a yearly
urinary microalbumin measurement

33.6

37

95

Proportion of females aged 50-74 to receive breast
cancer screening

73.7

81.1

74.4

Proportion of females aged 21-65 to receive cervical
cancer screening

84.5

93.0

46.4

Proportion of adults aged 50-75 to receive colorectal
cancer screening

52.1

70.5

63.0

Increase percent of tobacco screening in adults in
ambulatory care setting

62.4

68.6

100

Increase the proportion of PCP who assess BMI

48.7

53.6

100

Increase the percentage of adults aged 18 and older who
are vaccinated against seasonal influenza

38.1

70.0

43

Increase the percentage of high-risk adults age 18 to 64
who are vaccinated against pneumococcal disease

16.6

60.0

29.7

Increase the percentage of adults aged 65 and older who
are vaccinated against pneumococcal disease

60.0

90.0

72.2

HP2020 Objective
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